Pembrolizumab in a combination with chemotherapy improves the general survival at application in the first line at patients with NMRL which have no PD-L1 expression in a tumor

08.10.2019 - Company MSD reported that pembrolizumab in a combination with chemotherapy (HT) showed improvement of the general survival (GS), the survival without progressing (SWP) and the frequency of objective answers (FOA) at patients with a widespread nemelkokletochny cancer of easy (NMRL) without PD-L1 expression in a tumor (TPS...